At a glance
(thousands of €, if not stated otherwise) |
Second quarter of 2020 |
Second quarter of 2019 |
Six months ended 30 June 2020 |
Six months ended 30 June 2019 |
Full year 2019 |
||
|
|||||||
Income statement |
|
|
|
|
|
||
Revenues |
103,600 |
58,738 |
201,773 |
91,785 |
844,985 |
||
Other income |
14,059 |
8,852 |
22,802 |
16,724 |
50,905 |
||
R&D expenditure |
(149,114) |
(94,372) |
(265,877) |
(177,567) |
(427,320) |
||
S, G&A expenses |
(54,759) |
(17,585) |
(89,497) |
(28,552) |
(98,278) |
||
Operating expenses |
(203,873) |
(111,958) |
(355,374) |
(206,119) |
(525,597) |
||
Operating profit/loss (-) |
(86,214) |
(44,367) |
(130,799) |
(97,610) |
370,292 |
||
Net financial results |
(28,454) |
(2,820) |
(34,135) |
1,834 |
(220,233) |
||
Taxes |
(373) |
(61) |
(709) |
(129) |
(214) |
||
Net profit / loss (-) |
(115,042) |
(47,249) |
(165,643) |
(95,905) |
149,845 |
||
Balance sheet |
|
|
|
|
|
||
Cash and cash equivalents |
2,384,220 |
1,147,923 |
2,384,220 |
1,147,923 |
1,861,616 |
||
Current financial investments |
3,182,276 |
- |
3,182,276 |
- |
3,919,216 |
||
R&D incentives receivables |
116,629 |
94,288 |
116,629 |
94,288 |
115,356 |
||
Assets |
5,851,564 |
1,357,848 |
5,851,564 |
1,357,848 |
6,068,609 |
||
Shareholders' equity |
2,773,263 |
1,143,367 |
2,773,263 |
1,143,367 |
2,875,658 |
||
Deferred income |
2,823,833 |
96,325 |
2,823,833 |
96,325 |
3,000,646 |
||
Other liabilities |
254,468 |
118,157 |
254,468 |
118,157 |
192,305 |
||
Cash flow |
|
|
|
|
|
||
Operational cash flow/operational cash burn (-)(1) |
(147,088) |
(76,200) |
(230,486) |
(152,545) |
3,162,804 |
||
Cash flow used (-)/generated in operating activities |
(140,955) |
(70,041) |
(209,829) |
(141,740) |
3,208,617 |
||
Cash flow generated/used (-) in investing activities |
(216,836) |
(5,263) |
712,804 |
(8,661) |
(3,764,660) |
||
Cash flow generated in financing activities |
16,316 |
3,428 |
20,246 |
5,661 |
1,335,751 |
||
Increase/decrease (-) in cash and cash equivalents |
(341,473) |
(71,876) |
523,222 |
(144,740) |
779,708 |
||
Transfer to current financial investments |
- |
- |
- |
- |
(198,922) |
||
Effect of exchange rate differences on cash and cash equivalents |
(17,878) |
(3,102) |
(617) |
1,866 |
(9,966) |
||
Cash and cash equivalents at end of the period |
2,384,220 |
1,147,923 |
2,384,220 |
1,147,923 |
1,861,616 |
||
|
|
|
|
|
|
||
Current financial investments at end of the period |
3,182,276 |
- |
3,182,276 |
- |
3,919,216 |
||
Total current financial investments and cash and cash equivalents at end of the period |
5,566,496 |
1,147,923 |
5,566,496 |
1,147,923 |
5,780,832 |
||
Financial ratios |
|
|
|
|
|
||
Number of shares issued at end of the period |
65,254,562 |
54,823,101 |
65,254,562 |
54,823,101 |
64,666,802 |
||
Basic income / loss (-) per share (in €) |
(1.77) |
(0.86) |
(2.55) |
(1.76) |
2.60 |
||
Diluted income / loss (-) per share (in €) |
(1.77) |
(0.86) |
(2.55) |
(1.76) |
2.49 |
||
Share price at end of the period (in €) |
175.05 |
113.45 |
175.05 |
113.45 |
186.50 |
||
Total group employees at end of the period (number) |
1,280 |
837 |
1,280 |
837 |
1,003 |
||
Employees per site as of 30 June 2020
(total: 1,280 employees)
